AzTrials
AzTrials

Advanced Solid TumorPhase 1/2NCT06953323

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

A Phase 1/2 study testing WJB001 Capsules+Paclitaxel/Paclitaxel-albumin, WJB001 Capsules+carboplatin/Nedaplatin and WJB001 Capsules+Paclitaxel+carboplatin in people with Advanced Solid Tumor, run by Wigen Biomedicine Technology (Shanghai) Co., Ltd. at 10 sites in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a phase I/II study to preliminarily explore of the safety, tolerability, pharmacokinetics, and efficacy of WJB001 combination therapy, consisting of three stages: Dose escalation (Phase Ia), dose extension (Phase Ib), and efficacy extension (Phase II). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Advanced Solid Tumor
What is being tested?
WJB001 Capsules+Paclitaxel/Paclitaxel-albumin, WJB001 Capsules+carboplatin/Nedaplatin and WJB001 Capsules+Paclitaxel+carboplatin
Could I receive a placebo?
No, everyone receives an active treatment
How many people
86 participants
Where
10 sitesChina
Study dates
10 Jul 2025to 30 Dec 2029
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participants must meet all of the following inclusion criteria:
  • Participants voluntarily participate in this study with full informed consent and sign an informed consent form（ICF）.
  • Age ≥ 18 years old, No gender limitation,witih BMI (Body Mass Index) ≥ 18.5.
  • Patients diagnosed with Advanced solid tumors confirmed by pathology and/or cytology, must meet the following criteria:
  • For the detection of biomarkers such as CCNE1,tumor tissue samples must be provided from the patient
  • CCNE1 overexpression confirmed by central laboratory immunohistochemistry (IHC) in tumor tissue
Show all 19Show fewer
  • Have failed or are intolerant to standard treatments or have no available standard treatments options(Applicable to Dose escalation phase)
  • For patients with platinum-sensitive or platinum-resistant recurrent advanced high-grade serous ovarian cancer(HGSOC), fallopian tube cancer, or peritoneal cancer, as well as advanced uterine serous carcinoma (USC)
  • There is at least one Target lesion that meets the definition of RECIST v1.1 criteria, and the selected target lesion has not received biopsy in the past two weeks.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • Expected survival time ≥12 week.
  • Having Adequate hematologic and organ function, the following laboratory tests should be conducted within 7 days prior to the first administration of the investigational drug (No blood transfusion, without receiving hematopoietic stimulating factors or human albumin preparations within 14 days prior to the examination):
  • Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L
  • Hemoglobin>90 g/L
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × upper limit of normal (ULN)(for patients with liver metastases ，AST and ALT≤ 5.0× ULN)
  • Total bilirubin (TBIL) ≤ 1.5 × ULN(for patients enrolled in Arm A，Arm C and Arm G , TBIL≤ 1.2.5× ULN；patients with Gilbert's Syndrome，TBIL≤3×ULN and Direct bilirubin≤ 1.5 × ULN)
  • Serum creatinine(Cr) ≤1.5×ULN or Creatinine clearance (Ccr, calculated using Cockcroft-Gault formula) ≥45 mL/min (for patients enrolled in Arm B,Arm C and Arm G, Creatinine clearance ≥60 mL/min)
  • All acute toxic reactions due to prior antitumor therapy or surgery have resolved to baseline level or grade ≤ 1 defined by NCI CTCAE V5.0 (except alopecia or pigmentation).
  • The effective contraceptive methods must be used.

Who cannot join

  • Participants must not meet any of the following exclusion criteria:
  • General condition.
  • Pregnant or lactating women
  • Any known allergies to or contraindications to components of the study drug
  • History of substance abuse
  • History of alcohol abuse or consumption of more than 28 units of alcohol per week (1 unit =285 ml beer or 25 ml spirits (40%v/v) or 100 ml wine)
Show all 33Show fewer
  • Previous or current treatment:
  • Previous or current treatment with Wee1 inhibitors,as well as CDK2, PKMYT1, PARG, and ATR inhibitors
  • Having received cytotoxic chemotherapy drugs, traditional Chinese medicine treatment indicated for anti-tumor purposes, or other anti-tumor drugs (such as small-molecule targeted therapy, etc.) within 14 days before the first administration of the study treatment; or having received investigational drugs, macromolecular drugs with anti-tumor effects (such as monoclonal antibodies, antibody-drug conjugates, or bispecific antibodies, etc.) within 28 days before the first administration of the study treatment; or requiring continued treatment with these drugs during the study period
  • Currently using moderate or strong CYP3A inhibitors or inducers, or other products (such as grapefruit juice), or P-gp inhibitors or inducers, and the drug discontinuation time is less than 5 half-lives of the drug or 14 days (whichever is shorter) before the first administration of WJB001
  • Known with having a organ transplant or stem cell transplant; Having major surgery or severe trauma (excluding needle biopsy for sample collection) within 4 weeks prior to the first administration of study drug;Minor surgery within 7 days before the first dose, excluding the placement of vascular infusion devices;
  • Radiation therapy was administered within 21 days prior to the first administration of study drug, except for cases where radiation therapy is less than or equal to 5% of bone marrow volume, and regardless of when radiation therapy was received, the patients can be included in the study;Any local treatment for cancer such as thoracoabdominal perfusion therapy was received within 14 days before the first administration
  • Poorly controlled pleural effusion, ascites, or pericardial effusion (poor control is defined as requiring puncture and drainage during the screening period or having undergone drainage within 3 months before the first dose of medication)
  • Patients with a history of drug-related adverse events leading to permanent discontinuation during previous treatment with anti-PD-(L)1 antibodies or analogs or other therapies targeting the same pathway; (applicable only to Arm F and/or Arm G)
  • Patients with a history of drug-related adverse events leading to permanent discontinuation during previous treatment with anti-VEGF monoclonal antibodies or analogs or other therapies targeting the same pathway; (applicable only to Arm E, F, and/or Arm G)
  • Having received any live vaccine or live-attenuated vaccine within 28 days prior to the first dose, or anticipated to require such vaccination during the study period
  • Having received antiplatelet therapy within 10 days prior to the first dose (aspirin ≤325 mg/day is allowed) or anticoagulant therapy for treatment purposes (prophylactic anticoagulation is allowed);
  • Patients with primary platinum-refractory disease (defined as disease progression during the first platinum-containing regimen or within 4 weeks)
  • Past medical history, present medical history and abnormal laboratory indicators:
  • Having active gastrointestinal abnormalities including, but not limited to, inability to take oral medication, need for intravenous nutritional support, peptic ulcer, chronic diarrhea (e.g., Crohn's disease, irritable bowel syndrome), or vomiting or other factors that the investigator deems may significantly affect absorption, metabolism, or excretion of the drug (such as a small intestinal stoma, etc.)
  • There was a history of severe eye diseases in the past (excluding permanent blindness caused by the disease), and it has not been recovered Grade ≤1 at present
  • Patients with active brain metastases (except if they have central nervous system (CNS) metastases confined to the supratentorial or cerebellar region, having received adequately treatment (surgery or radiotherapy), having maintained radiological stability for at least 4 weeks, and do not require corticosteroids for symptom control)
  • Patients currently have suffered carcinomatous meningitis, spinal cord compression, and hepatic encephalopathy, etc
  • Severe or poorly controlled hypertension, including a history of hypertensive crisis or hypertensive encephalopathy; having Adjustment of antihypertensive medication due to poor blood pressure control within 2 weeks before the first dose;Systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg during the screening period
  • Having any of the following cardiac criteria: cardiomyopathy, ischemic heart disease, valvular disease, hypertensive heart disease, heart failure, presyncope or syncope of unexplained or cardiovascular origin, ventricular tachycardia, ventricular fibrillation, or cardiac arrest. At rest, the average corrected QT interval (QTc, calculated using Fridericia's correction formula) obtained from three electrocardiogram (ECG) examinations is >450 ms for males or >470 ms for females (repeated three times). Various clinically significant arrhythmias, conduction abnormalities, and resting ECG morphological abnormalities, such as complete left bundle branch block, third-degree atrioventricular block, second-degree atrioventricular block, PR interval >250 ms. Echocardiography shows that the left ventricular ejection fraction (LVEF) < 50%. Various factors that may increase the risk of QTc prolongation or arrhythmia events, such as heart failure, hypokalemia, a history of congenital long QT syndrome or torsades de pointes (TdP), a family history of long QT syndrome in a direct relative or sudden unexplained death of a direct relative before the age of 40, and currently using any drug known to prolong the QT interval
  • Having clinically significant bleeding symptoms or obvious bleeding tendency within 4 weeks before the first dose, such as gastrointestinal bleeding, gastric ulcer bleeding, obvious gross hematuria, or suffering from vasculitis,etc; Or have evidence of major coagulation disorders within 6 months before the first administration of the drug, such as events like deep vein thrombosis of the lower extremities, myocardial infarction, etc
  • Having active HBV and HCV infection: if HBsAg is positive or/and anti-HBC is positive, blood HBV DNA need to be tested to confirm that it is higher than the limit of quantitative detection; If anti-HCV is positive, HCV RNA need to be tested to confirm that the HCV viral copy number exceeds the quantitative detection limit
  • known history of human immunodeficiency virus infection or having a positive result for serum anti-HIV test
  • History of other primary solid tumor(except for the radically cured solid tumor ,which is inactive and has a very low risk of recurrence for ≥5 years before screening）; Non-melanoma skin cancer or lentigo maligna that has been adequately treated andshows no evidence of disease recurrence; Carcinoma in situ, such as cervical carcinoma in situ, that has been adequately treated and shows no evidence of disease recurrence)
  • Severe active infectious diseases or other diseases that seriously affect the safety of the first medication occurred during the screening period
  • Within 2 years prior to the first use of medication, there are active autoimmune diseases that require systemic treatment (such as corticosteroids or immunosuppressive drugs), including but not limited to: systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, vasculitis, etc. However, screening is allowed for hypothyroidism, adrenal or pituitary dysfunction, type I diabetes that can be controlled only by hormone replacement therapy, psoriasis or vitiligo that does not need systematic treatment, and childhood asthma/allergy that has been cured
  • History of interstitial lung disease or history of non infectious pneumonia and treatment with corticosteroids, or screening imaging showing evidence of active pneumonia
  • The investigator deems that the patient has other factors that may affect the research results and interfere with their participation in the entire research process. These factors include, but are not limited to, past or current physical conditions (such as mental disorders, optic nerve atrophy, excessive low body weight, severe hydronephrosis, or thyroid dysfunction), treatments, or abnormal laboratory test results. The subject is unwilling to abide by various procedures, restrictions, and requirements of the study, is unable to cooperate or undergo MRI or CT scans, or has psychological or social conditions that may interfere with their participation in the study or have an impact on the evaluation of the study results, etc

Trial locations and contacts

10 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Yirong Zhao, Master contact

15221069447

yrzhao@wigenbio.com

10 sites in 1 country

China10 sites, 10 recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100021

    Lingying Wu, Professor, 13910865483, wulingying@csco.org.cn

    Lingying Wu, Professor

    Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, 410000

    Jie Tang, Professor, 15274836636, tangjie@hnca.org.cn

    Jie Tang, Professor

    Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350000

    An Lin, Professor, 13805015679, linan640906@163.com

    An Lin, Professor

    Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, 510000

    Jundong Li, Professor, 13602859866, lijd@sysucc.org.cn

    Jundong Li, Professor

    Recruiting

  • Sun Yat-sen Hospital, Sun Yat-sen University

    Guangzhou, Gunagdong, 510000

    Qunxian Rao, Professor, 13902250700, badger777@163.com

    Qunxian Rao, Professor

    Recruiting

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310000

    Xuejun Chen, Professor, 13757119632, startchen@zju.edu.cn

    startchen@zju.edu.cn Chen, Professor

    Recruiting

  • Tumor Hospital Affiliated to Guangxi Medical University

    Nanning, Guangxi, 530000

    Jieqing Zhang, Professor, 15278015900, 1583825050@qq.com

    Jieqing Zhang, Professor

    Recruiting

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, 110000

    Danbo Wang, Professor, 18940251157, danbo_wang@126.com

    Danbo Wang, Professor

    Recruiting

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, 110000

    Funan Liu, Professor, 13609877906, lfn_clinical@126.com

    Funan Liu, Professor

    Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430023

    Guilin Li, Professor, 13307187507, lgl6714@163.com

    Guilin Li, Professor

    Recruiting

Other trials in China

About this study

Official title: A Dose-escalation, Dose-expansion and Efficacy Extension Phase I/II Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of WJB001 Combination Therapy in Patients With Advanced Solid Tumors

This is a phase I/II study to preliminarily explore of the safety, tolerability, pharmacokinetics, and efficacy of WJB001 combination therapy, consisting of three stages: Dose escalation (Phase Ia), dose extension (Phase Ib), and efficacy extension (Phase II). The preliminary plan includes seven combination therapy regimens, namely Arm A: WJB001+taxanes (A1: WJB001+paclitaxel, A2: WJB001+albumin paclitaxel); Arm B: WJB001+platinum (B1: WJB001+carboplatin, B2: WJB001+nedaplatin); Arm C: WJB001+paclitaxel+carboplatin; Arm D: WJB001+PARP inhibitor; Arm E: WJB001+VEGF inhibitor; Arm F:WJB001+JS207/JS001（F1：WJB001+JS207，F2：WJB001+JS001）；Arm G：WJB001+JS207/JS001+paclitaxel+carboplatin（G1: WJB001+JS207 +paclitaxel+carboplatin；G2：WJB001+JS001+paclitaxel+carboplatin）.

Read the detailed description

The study is a multicenter,phase I/II clinical trial, divided into three parts:

In the Dose Escalation phase(Phase Ia): BOIN design were used to search the Maximum tolerated dose (MTD), allowing to increase or decrease the dose of one or separate drugs in the combination for dosage exploration.Recruitment by Arm, estimate 5 7 cohort, with several dose levels planned for each cohort:

In the Arm A/B/C combination therapy, chemotherapy (taxanes, platinum) is administered for a maximum of 6 cycles. After chemotherapy, WJB001 monotherapy is used to maintain treatment until the subject's disease progresses or withdrawl; In the Arm D combination therapy, the PARP inhibitor, such as Niraparib, is administered every 21 days in a cycle until the subject's disease progresses or withdrawl.

In the Arm E combination therapy, as an example, Bevacizumab can be treated for a maximum of 22 cycles or unacceptable side effects occur (whichever occurs first), and then Bevacizumab treatment is terminated and maintained with WJB001 monotherapy until the subject's disease progression or withdrawal In the Arm F1 combination therapy, JS207 is treated for 2 years or with unacceptable side effects (whichever occurs first) before disease progression occurs, and then JS207 treatment is terminated. Arm F2/G2: JS001 Treat until unacceptable side effects occur (whichever occurs first) before disease progression occurs.Upon termination of JS207/JS001 treatment, maintenance therapy with WJB001 monotherapy will be administered at a dose of 160 mg or the current dose (as determined by the investigator), until disease progression or withdrawal.

In the Arm G combination therapy, chemotherapy (paclitaxel, platinum) is administered for up to 6 cycles,WJB001+JS207/JS001 is maintained at the RP2D dose of the two drugs explored in Arm F or the current dose (determined by Investigator).

In the Dose Expansion phase(Phase Ib): 1 to 2 dose levels for each group will be selected the sponsor and the SMC based on the previous data, to further evaluate the preliminary efficacy, safety, tolerability and pharmacokinetic characteristics of the combination therapy in the target population, and confirm the RP2D dose of different combination regimens.

Efficacy Expansion Stage(Phase II): At the RP2D regimen determined in the Phase IB study, to explore the efficacy, safety, tolerability and pharmacokinetic characteristics of WJB001 combination therapy in the target population. And 2 to 3 cohorts is preliminarily planned for expansion and the "Simon Two-Stage" design is adopted.

Being tested
WJB001 Capsules+Paclitaxel/Paclitaxel-albumin, WJB001 Capsules+carboplatin/Nedaplatin, WJB001 Capsules+Paclitaxel+carboplatin, WJB001 Capsules+Niraparib, WJB001 Capsules+Bevacizumab

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • WJB001 Capsules+Paclitaxel/Paclitaxel-albuminDrug

    Also called Wee1 inhibitor+ Taxol/Abraxane

    WJB001 Capsules:120mg(or 160mg,80mg,40mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Paclitaxel:80 mg/m2(or 60 mg/m2 ,50 mg/m2), Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles; Paclitaxel-albumin:260mg/m2(220mg/m2,180mg/m2),On day 1, intravenous infusion, 21 days 1 cycle, up to 6 cycles

  • WJB001 Capsules+carboplatin/NedaplatinDrug

    Also called Wee1 inhibitor+ PARAPLATIN/Aqupla

    WJB001 Capsules:80mg(or160mg, 120mg,40mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Carboplatin:AUC 5 mg/ml*min(or 4mg/ml*min,3mg/ml*min), Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles; Nedaplatin:100mg(80mg/m2 ,60mg/m2), Day 1, intravenous infusion, 21 days 1 cycle, up to 6 cycles;

  • WJB001 Capsules+Paclitaxel+carboplatinDrug

    Also called Wee1 inhibitor+ PARAPLATIN+Taxol

    WJB001 Capsules:40mg(or 160mg, 120 mg,80mg,60mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Paclitaxel:60 mg/m2, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles; Carboplatin:AUC 2mg/ml*min, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;

  • WJB001 Capsules+NiraparibDrug

    Also called Wee1 inhibitor+ Zejula

    WJB001 Capsules:120mg(or 160mg,80mg,40mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Niraparib:Niraparib:300mg(or 200mg,100mg),Oral,QD,Every 21 days;

  • WJB001 Capsules+BevacizumabDrug

    Also called Wee1 inhibitor+ Avastin

    WJB001 Capsules:120mg(or 160mg,80mg,40mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Bevacizumab:15mg/kg(or 7.5mg/kg),intravenous infusion, 21 days 1 cycle, up to 22 cycles or unacceptable side effects；

  • WJB001 Capsules+JS207/JS001Drug

    Also called Wee1 inhibitor+JS207/Toripalimab

    WJB001 Capsules:120mg/160mg ( (or referring to previously conducted cohorts or other clinical studies ),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; JS207:10mg/kg(or lower dosage),intravenous infusion, 21 days 1 cycle, up to 2 years or unacceptable side effects； Toripalimab:240 mg,intravenous infusion,21 days 1 cycle, up to desease progression or unacceptable side effects；

  • WJB001 Capsules+Paclitaxel+carboplatin+JS207/ToripalimabDrug

    WJB001 Capsules:40mg (or referring to previously conducted cohorts or other clinical studies ),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; JS207:10mg/kg(or lower dosage),intravenous infusion, 21 days 1 cycle, up to 2 years or unacceptable side effects Toripalimab:240 mg,intravenous infusion,21 days 1 cycle, up to desease progression or unacceptable side effects Paclitaxel:60 mg/m2, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles; Carboplatin:AUC 2mg/ml*min, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;

Study groups in NCT06953323
Study groupRoleWhat they receive
WJB001 capsules with TaxanesExperimentalIf needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia: Participants with advanced solid tumor will receive WJB001 capsules at escalating dose levels after a maximum of 6 cycles of Paclitaxel/Paclitaxel-albumin. Phase Ib/II: Participants with High-grade serous ovarian cancer（HGSOC）,fallopian tube cancer,peritoneal cancer ,or Uterine Serous Carcinoma(USC) will receive WJB001 capsules at expansion dose levels after a maximum of 6 cycles of carboplatin/Nedaplatin.
Receives: Drug: WJB001 Capsules+Paclitaxel/Paclitaxel-albumin
WJB001 capsules with PlatinumExperimentalIf needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia: Participants with advanced solid tumor will receive WJB001 capsules at escalating dose levels after a maximum of 6 cycles of carboplatin/Nedaplatin. Phase Ib/II: Participants with High-grade serous ovarian cancer（HGSOC）,fallopian tube cancer,peritoneal cancer ,or Uterine Serous Carcinoma(USC) will receive WJB001 capsules at expansion dose levels after a maximum of 6 cycles of carboplatin/Nedaplatin.
Receives: Drug: WJB001 Capsules+carboplatin/Nedaplatin
WJB001 capsules with paclitaxel+carboplatinExperimentalIf needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia: Participants with advanced solid tumor will receive WJB001 capsules at escalating dose levels after a maximum of 6 cycles of Paclitaxel+carboplatin. Phase Ib/II: Participants with High-grade serous ovarian cancer（HGSOC）,fallopian tube cancer,peritoneal cancer ,or Uterine Serous Carcinoma(USC) will receive WJB001 capsules at expansion dose levels iafter a maximum of 6 cycles of Paclitaxel+carboplatin.
Receives: Drug: WJB001 Capsules+Paclitaxel+carboplatin
WJB001 capsules with PARPiExperimentalIf needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia: Participants with advanced solid tumor will receive WJB001 capsules at escalating dose levels in combination with PAPPi. Phase Ib/II: Participants with High-grade serous ovarian cancer,fallopian tube cancer（HGSOC）,peritoneal cancer ,or Uterine Serous Carcinoma(USC) will receive WJB001 capsules at expansion dose levels in combination with PAPPi.
Receives: Drug: WJB001 Capsules+Niraparib
WJB001 capsules with VEGFiExperimentalIf needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia: Participants with advanced solid tumor will receive WJB001 capsules at escalating dose levels in combination with VEGFi. Phase Ib/II: Participants with High-grade serous ovarian cancer（HGSOC）,fallopian tube cancer,peritoneal cancer ,or Uterine Serous Carcinoma(USC) will receive WJB001 capsules at expansion dose levels in combination with VEGFi.
Receives: Drug: WJB001 Capsules+Bevacizumab
WJB001 capsules with Anti-PD-1 and VEGF bispecific antibodies/ Anti-PD-1 antibodiesExperimentalIf needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia: Participants with advanced solid tumor will receive WJB001 capsules at escalating dose levels in combination with Anti-PD-1 and VEGF bispecific antibodies/ Anti-PD-1 antibodies . Phase Ib/II: Participants with High-grade serous ovarian cancer（HGSOC）,fallopian tube cancer,peritoneal cancer ,or Uterine Serous Carcinoma(USC) will receive WJB001 capsules at expansion dose levels in combination with Anti-PD-1 and VEGF bispecific antibodies/ Anti-PD-1 antibodies.
Receives: Drug: WJB001 Capsules+JS207/JS001
WJB001 capsules with paclitaxel and carboplatin, together with Anti-PD-1 and VEGF bispecific antiboExperimentalIf needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia:Participants with advanced solid tumor will receive WJB001 capsules in combination with paclitaxel and carboplatin, together with Anti-PD-1 and VEGF bispecific antibodies/ Anti-PD-1 antibodies . Phase Ib and II:Participants with High-grade serous ovarian cancer,fallopian tube cancer,peritoneal cancer ,or Uterine Serous Carcinoma will receive WJB001 capsules in combination with paclitaxel and carboplatin, together with Anti-PD-1 and VEGF bispecific antibodies/ Anti-PD-1 antibodies .
Receives: Drug: WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Dose limited toxicity (DLT)

    Incidence of Dose limited toxicity(DLT)

    Measured: 21day

  2. Adverse event (AE)

    Incidence and severity of adverse event (AE), Abnormal changes in laboratory and other tests of clinical significance

    Measured: 3 years

  3. Serious adverse event (SAE)

    Incidence and severity of Serious adverse event (SAE)

    Measured: 3 years

  4. Maximum tolerated dose (MTD)

    Maximum tolerated dose (MTD)

    Measured: 2 years

  5. Recommended phase II dose (RP2D)

    Recommended phase II dose (RP2D)

    Measured: 2 years

  6. Objective response rate(ORR)

    Objective response rate(ORR) evaluated by Investigator per RECIST v1.1 in Phase II

    Measured: 3 years

Secondary outcomes (22)

  1. Peak time(Tmax)

    Pharmacokinetic (PK) parameter : Peak time(Tmax) after a single dose of WJB001/JS207；

    Measured: 4 Months

  2. Maximum plasma concentration (Cmax)

    Maximum plasma concentration (Cmax) after a single dose of WJB001/JS207;

    Measured: 4 Months

  3. (AUC 0-t)

    Area under blood concentration - time curve(AUC 0-t) after a single dose of WJB001/JS207;

    Measured: 4 Months

  4. (AUC 0-∞)

    Area under blood concentration - time curve(AUC 0-∞) after a single dose of WJB001/JS207;

    Measured: 4 Months

  5. Apparent volume of distribution (Vd/F)

    Apparent volume of distribution (Vd/F) after a single dose of WJB001/JS207;

    Measured: 4 Months

  6. Clearance rate (CL/F)

    Clearance rate (CL/F) after a single dose of WJB001/JS207;

    Measured: 4 Months

  7. Elimination half-life time ( t1/2)

    Elimination half-life time ( t1/2) after a single dose of WJB001/JS207;

    Measured: 4 Months

  8. Steady state peak concentration(Cmax,ss)

    Steady state peak concentration(Cmax,ss) after multiple administration for WJB001/JS207;

    Measured: 4 Months

  9. Steady state valley concentration(Cmin,ss)

    Steady state valley concentration(Cmin,ss) after multiple administration for WJB001/JS207;

    Measured: 4 Months

  10. Average steady-state plasma concentration(Cav,ss)

    Average steady-state plasma concentration(Cav,ss) after multiple administration for WJB001/JS207;

    Measured: 4 Months

  11. Steady state peak time(Tmax,ss)

    Steady state peak time(Tmax,ss) after multiple administration for WJB001/JS207;

    Measured: 4 Months

  12. Steady state Area under blood concentration - time curve(AUC0-t,ss)

    Steady state Area under blood concentration - time curve(AUC0-t,ss) after multiple administration for WJB001/JS207;

    Measured: 4 Months

  13. Accumulation Index ( RAC)

    Accumulation Index ( RAC) after multiple administration for WJB001/JS207;

    Measured: 4 Months

  14. Anti-drug antibodies (ADA)

    Incidence and titer of anti-drug antibodies (ADA) for JS207；

    Measured: 2 years

  15. Neutralizing Antibody (NAb)

    Incidence of Antibody (NAb) for JS207

    Measured: 2 years

  16. Objective response rate(ORR)

    Objective response rate(ORR) evaluated by Investigator per RECIST v1.1 in Phase I

    Measured: 3 years

  17. Duration of response (DOR)

    Efficacy endpoints : Duration of response (DOR) evaluated by Investigator per RECIST v1.1

    Measured: 3 years

  18. Disease control rate (DCR)

    Efficacy endpoints: Disease control rate (DCR) evaluated by Investigator per RECIST v1.1；

    Measured: 3 years

  19. Time of Disease Progression (TTP)

    Time of Disease Progression (TTP) evaluated by Investigator per RECIST v1.1

    Measured: 3 years

  20. Progression-free survival (PFS)

    Progression-free survival (PFS) evaluated by Investigator per RECIST v1.1

    Measured: 3 years

  21. Overall survival (OS)

    Overall survival (OS) evaluated by Investigator per RECIST v1.1

    Measured: 3 years

  22. CCNE1

    The correlation between CCNE1 overexpression or amplification and therapeutic efficacy

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 May 2025
  2. Study start10 Jul 2025
  3. Primary completion30 Jun 2029 (estimated)
  4. Study completion30 Dec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
86 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06953323
Sponsor's protocol ID
WJB001-002-I
Status last verified
Sep 2026
First submitted
23 Apr 2025
Last updated
17 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing WJB001 Capsules+Paclitaxel/Paclitaxel-albumin, WJB001 Capsules+carboplatin/Nedaplatin and WJB001 Capsules+Paclitaxel+carboplatin in people with Advanced Solid Tumor, run by Wigen Biomedicine Technology (Shanghai) Co., Ltd. at 10 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 19 inclusion and 33 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Yirong Zhao, Master (15221069447, yrzhao@wigenbio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Dose limited toxicity (DLT) (time frame: 21day). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06953323.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in